



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7310

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

21 April 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Prostate Cancer.

You asked:

1. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer treatment for:

- a. Prostate cancer (any stage)*
- b. Metastatic prostate cancer*

2. How many patients were treated for prostate cancer (any stage) in the past 3 months with:

- a. Androgen Deprivation Therapy (ADT) standalone*
- b. Abiraterone (Zytiga) in combination with any ADT*
- c. Abiraterone (Zytiga) - no ADT*
- d. Enzalutamide (Xtandi) in combination with any ADT*
- e. Enzalutamide (Xtandi) - no ADT*
- f. Apalutamide (Erleada) in combination with any ADT*
- g. Darolutamide (Nubeqa) in combination with any ADT*
- h. Cabazitaxel (Jevtana)*
- i. Docetaxel in combination with any ADT*
- j. Docetaxel – no ADT*
- k. Degarelix (Firmagon)*
- l. Olaparib (Lynparza)*

3. How many metastatic prostate cancer patients were treated in the past 3 months with:

- a. Androgen Deprivation Therapy (ADT) standalone*
- b. Apalutamide (Erleada) in combination with any ADT*
- c. Docetaxel in combination with any ADT*
- d. Docetaxel – no ADT*

Trust response:

1.

a. 142

b. 42

2.

a. We are unable to identify standalone. All patients have some chemotherapy treatments.

b. 22

c. 13

d. 43

e. 14

f. 2

g. 0

h. 1

i. 12

j. 4

k. 0

l. 1

3.

a. We are unable to identify standalone. All patients have some chemotherapy treatments.

b. 1

c. 3

d. 2